泊沙康唑预防或挽救性治疗血液病患者侵袭性真菌病的临床研究

目的 探讨泊沙康唑预防或挽救性治疗血液病患者侵袭性真菌病(IFD)的疗效及安全性.方法 回顾性分析2014年2月至2015年2月接受泊沙康唑预防或挽救性治疗IFD的25例血液病患者临床资料,患者平均年龄32.6岁(16～64岁).其中18例接受了泊沙康唑预防性治疗,7例接受了泊沙康唑挽救性治疗.结果 18例接受预防性治疗的患者在治疗期间或治疗结束后12周内,均没有出现IFD的临床表现(即无突破性真菌感染的病例),预防性治疗的平均疗程为21 d(14～35 d).7例接受挽救性治疗的患者均为伏立康唑治疗无效或不耐受者,挽救性治疗的总有效率为6/7,其中4例治愈,2例有效.所有患者中没有发现与泊沙康唑相关的明显不良反应.结论 泊沙康唑用于预防或挽救性治疗血液病患者IFD,均能够获得较好的临床疗效.

Clinical study on posaconazole for the prophylaxis or salvage treatment of invasive fungal disease in patients with hematological diseases

Objective To investigate the efficacy and safety of posaconazole in the prophylaxis or salvage treatment of invasive fungal disease (IFD) in patients with hematological diseases.Methods 25 patients with hematological diseases receiving posaconazole treatment from Feb 2014 to Feb 2015 were analyzed retrospectively.The patients' average age was 32.6 years old (16-64 years old).18 patients received posaconazole for IFD prophylaxis, and 7 patients for IFD salvage treatment.Results 18 patients receiving posaconazole for IFD prophylaxis had no clinical manifestation of IFD (that is no case of breakthrough fungal infection) during treatment or in the 12 weeks after treatment, and the average prophylaxis period was 21 d (14-35 d).Among 7 patients receiving posaconazole for IFD salvage treatment, 6 patients were effective, including 4 cases cured and 2 cases effective.There were no obviously side effects of posaconazole in these patients.Conclusion Posaconazole has good clinical response for IFD in the hematologic diseases patients whether in prophylaxis or in salvage treatment.